Clinical Trial

Evaluation of 611 in Combination With Topical Corticosteroid in Participants With Moderate to Severe Atopic Dermatitis

Active, Not Recruiting Phase 3
View on ClinicalTrials.gov →
Record status
This record was last updated July 14, 2025 (before its estimated October 12, 2025 completion). Its status may not reflect the trial's current state.
Summary
This is a randomized, double-blind, placebo-controlled, parallel-group study to evaluate the safety and efficacy of 611 when used in combination with topical corticosteroid (TCS) treatment compared with placebo in combination with TCS treatment for moderate-to-severe atopic dermatitis.
Protocol Amendment History 2 amendments
This ClinicalTrials.gov record has been amended 2 times since 2024-08-12; most recent amendment 2025-07-11.
Status change: Recruiting → Active, Not Recruiting 2025-07-11
Status change: Not Yet Recruiting → Recruiting 2024-09-29
Trial Details
NCT Number NCT06554847
Lead Sponsor Sunshine Guojian Pharmaceutical (Shanghai) Co., Ltd.
Conditions Dermatitis, Atopic, Eczema, Atopic
Enrollment 400 participants
Start Date 2024-09-23
Primary Completion 2025-10-12 (estimated)
Study Completion 2026-08-16 (estimated)
Updated on ClinicalTrials.gov 2025-07-14